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Six individuals with Ullrich congenital muscular dystrophy (UCMD) and mutations in the genes-encoding collagen VI, aging 5–
9, received 3–5mg/kg of cyclosporine A (CsA) daily for 1 to 3.2 years. The primary outcome measure was the muscle strength
evaluated with a myometer and expressed as megalimbs. The megalimbs score showed signiﬁcant improvement (P = 0.01) in 5
of the 6 patients. Motor function did not change. Respiratory function deteriorated in all. CsA treatment corrected mitochondrial
dysfunction, increased muscle regeneration, and decreased the number of apoptotic nuclei. Results from this study demonstrate
that long-term treatment with CsA ameliorates performance in the limbs, but not in the respiratory muscles of UCMD patients,
and that it is well tolerated. These results suggest considering a trial of CsA or nonimmunosuppressive cyclosporins, that retains
the PTP-desensitizing properties of CsA, as early as possible in UCMD patients when diaphragm is less compromised.
1.Introduction
Collagen VI (ColVI) is an ubiquitously expressed extra-
cellular matrix (ECM) protein consisting of three chains,
alpha1(VI), alpha2(VI), and alpha3(VI), encoded by the
COL6A1, COL6A2,a n dCOL6A3 genes, respectively. Muta-
tions in these three genes result in two major clinical forms,
Bethlem myopathy (BM [MIM158810]) [1] and Ullrich
congenital muscular dystrophy (UCMD [MIM 254090])
[2], and in the rarer myosclerosis myopathy (MM [MIM
255600]) [3]. BM is characterized by slowly progressive
axial and proximal muscle weakness with ﬁnger ﬂexion
contractures [4]. BM is usually mild [4], sometimes slowly
progressive with some aﬀected individuals over 50 years
of age needing aids for outdoors mobility [5]. In contrast,
UCMD is a severe disorder characterized by congenital
muscle weakness with axial and proximal joint contractures
and distal joint hypermobility [6]. Motor milestones are
delayed, and most of the children never acquire the ability
to walk independently [6]. Early, progressive and severe
respiratory involvement may require artiﬁcial ventilatory
supportintheﬁrstorseconddecadeoflife[7].Bothrecessive
and dominant ColVI mutations lead to BM and UCMD
[8, 9]. Prevalence has been estimated as 0.5:100,000 for BM2 Oxidative Medicine and Cellular Longevity
and 0.1:100,000 for UCMD [10], but these disorders are
probably underdiagnosed.
In the Col6a1−/− mutant mouse [11], muscle ﬁbres have
a loss of contractile strength associated with ultrastructural
alterationsconsistingofmarkeddilationsofthesarcoplasmic
reticulum, mitochondrial alterations, and nuclear features
of apoptosis [12]. Muscle ﬁbers of Col6a1−/− mice show
in addition signs of mitochondrial dysfunction. The rest-
ing mitochondrial membrane potential is unaﬀected, but
addition of oligomycin causes depolarization, an abnormal
response that is prevented by plating ﬁbers on ColVI or
by treating them with cyclosporin A (CsA) [12], a drug
which desensitizes the mitochondrial permeability transition
pore through binding to cyclophilin D [13]. In order to
establish whether mitochondria are also involved in the
pathogenesis of UCMD and BM, we studied muscle biopsies
and myoblasts from patients [14]. UCMD patients displayed
an increased rate of apoptosis in skeletal muscle in vivo and
in primary myoblast cultures [14]. The latter also displayed
a measurable fraction of altered mitochondria (with mor-
phological alterations ranging from shape changes to overt
swelling) and a latent mitochondrial dysfunction that could
be revealed by the addition of oligomycin, which caused
depolarization only in mitochondria from patients [14]. In
an open trial with CsA, we enrolled ﬁve patients representing
the clinical and molecular variety of ColVI myopathies [15].
Muscle biopsy was done before the onset of treatment and
mitochondria within the cells isolated from patients depo-
larized after the addition of oligomycin, conﬁrming in vivo
thepresenceofthelatentdysfunctionpreviouslyidentiﬁedin
Col6a1−/− mice and in cultures from UCMD patients [14].
One month after oral administration of CsA at a dose of
5mg/kgperdayintwodivideddoses,anewbiopsywastaken
at the contralateral site, and the experiment was repeated
[15]. Strikingly, the mitochondrial membrane potential
response to oligomycin was largely normalized in the muscle
cells from all patients, indicating that at the dose used in this
study, CsA reaches pharmacologically active concentrations
in muscle. In addition, unlike samples from normal donors
where apoptosis was undetectable, all samples from patients
had a sizeable number of apoptotic nuclei in the ﬁrst
biopsy, and treatment with CsA considerably decreased the
occurrence of apoptosis in all patients, indicating a cause-
eﬀect relationship between normalization of mitochondrial
function and decreased cell death. After CsA treatment, an
increased number of regenerating myoﬁbers were detected
and particularly prominent in the three younger patients
included in the study.
At the end of the one-month pilot trial treatment, the
parents of the three children requested to continue CsA
treatment. In addition, we were able to recruit three more
children with UCMD. Objective of this study is to evaluate
the eﬃcacy of a long-term treatment with CsA in six UCMD
patients.
2. Methods
2.1. Study Population. Six patients with Ullrich congenital
muscular dystrophy (UCMD), three originally enrolled in
the one-month pilot trial [15] and three new, received CsA
treatment.
2.2. Trial Design. This is a prospective long-term, open,
noncomparative, pilot clinical trial on the eﬃcacy of CsA in
patients with UCMD. The trial design conforms the EMEA
guidelines [16] for clinical trials in very rare diseases.
2.3. Eﬃcacy Measurements. The primary endpoint of the
trial was an increase in muscle strength as measured with
hand-held dynamometer. The secondary endpoints were the
eﬀect of CsA on the change in muscle mass, in motor
function, and in respiratory function in patients with
UCMD. In two of the new patients, the biological endpoint
was the evaluation of biomarkers of mitochondrial function,
apoptosis, and regeneration at baseline and after 3 months of
CsA treatment.
Muscle strength was measured by maximum voluntary
isometric contraction, with a hand-held dynamometer (Cit
Technics, Groningen, The Netherlands) to determine the
megalimbs, a composite score resulting from the sum of
bilateral muscle strength of elbow ﬂexion, hand grip, knee
ﬂexion, and knee extension. Measurements obtained by
standard techniques and in standard position were repeated
three times, and the best score was noted [17]. We have
already provided evidence of reliability and sensitivity of this
technique [17, 18], which we have employed in clinical trials
[19].
The forced vital capacity was measured by a standard
breathing test with a spirometer.
The 6-minute walking distance test was performed in the
two patients able to walk [20].
The motor function was evaluated with the Muscular
Dystrophy Functional Grading Scale for functional evalua-
tion [21].
Muscle mass and body fat were evaluated by dual-energy
X-ray densitometer (DXA).
Measurements of body composition were performed
with the Norland XR-36 DXA (Norland, Fort Atkinson, Wis)
with the subject supine. DXA estimates of body composition
are based on a three-compartment model measuring bone
mineral content (BMC), fat tissue mass (FTM), and lean
tissue mass (LTM). Total body bone mineral content (BMD)
is given as a Z score to compare with the normal range for
children of the same age [22]. Body fat was also estimated
with the body mass index (BMI) based on an individual’s
weight and height (wt/ht2). Diﬀerent from adult, to interpret
BMI in children, age and sex should be taken into account
given that the amount of body fat changes with age and
diﬀers between girls and boys [23]. The CDC BMI-for-age
growth charts for girls and boys take into account these
diﬀerences and allow translation of a BMI number into a
percentile for a child’s or teen’s sex and age [23].
We obtained muscle biopsies from healthy donors and
patients after informed consent and approval of the Ethics
Committee of the University of Ferrara. Muscle biopsy of the
tibialisanteriorwasperformedbeforeandafteronemonthof
treatment in the ﬁrst three patients [15] and after 3 monthsOxidative Medicine and Cellular Longevity 3
of full dose treatment in the last two patients. No muscle
biopsy was done in patient 4, sibling of patient 2, in whom
the positive eﬀect of CsA in vivo was already shown.
The preparations of the muscle biopsy for cell culture
and immunocytochemistry have been extensively described
[15]. In particular, early regenerating ﬁbers [24–27]w e r e
detected by immunoﬂuorescence analysis with antidevel-
opmental myosin heavy chain (dMHC) (Novocastra clone
RNMy2/9D2, which recognize a myosin heavy chain embry-
onic form), and desmin antibodies [15], and necrosis with
histochemical analysis of acid phosphatase and immuno-
histochemical detection of complement C5b-9 deposition
within muscle ﬁbers [28]. For statistical analysis of regener-
ation, 1,000 ﬁbers from three diﬀerent regions of the biopsy
for each sample were considered.
2.4. Detection of Apoptosis. We measured the rate of apopto-
sis in muscle biopsies using the TUNEL method [15]. Seven-
micrometer-thickfrozensectionswerepreparedfrommuscle
biopsies, ﬁxed in 50% acetone/50% methanol, and processed
for TUNEL analysis by using the Apoptag peroxidase in
situ apoptosis detection kit (Chemicon). Visualization of
all nuclei was performed by staining with Hoechst 33258
(Sigma). The number of TUNEL-positive nuclei was deter-
mined in randomly selected ﬁelds with a Zeiss Axioplan
microscope (×40 magniﬁcation) equipped with a digital
camera. For each biopsy, 30–85 ﬁelds containing muscle
ﬁbers and covering a total area of ∼ =1–7mm2 were observed.
2.5. Mitochondrial Membrane Potential Assay. Mitochon-
drial membrane potential was measured based on the ac-
cumulation of TMRM (Molecular Probes) [29]. Primary
cell cultures obtained from patient biopsies were plated
within 4h of the surgical biopsy in complete medium
plus 20% FCS on laminin/poly-L-lysine-coated coverslips
(BD Laboratories), and allowed to attach and spread for
9–14h. The medium was then replaced with serum-free
DMEM supplemented with 10nM TMRM for 30min, and
cellular ﬂuorescence images were acquired with an Olympus
IX71/IX51 inverted microscope, equipped with a xenon light
source (75W) for epiﬂuorescence illumination and with a
12-bit digital cooled CCD camera (Micromax, Princeton
Instruments). Data were acquired and analyzed using Cell
R Software (Olympus). For detection of ﬂuorescence, 568 ±
25nm band-pass excitation and 585nm long-pass emission
ﬁlter settings were used. Images were collected with exposure
time of 100msec using a 40x, 1.3NA oil immersion objective
(Nikon) for the patients’ cells. The extent of cell and hence
mitochondrialloadingwithpotentiometricprobesisaﬀected
by the activity of the plasma membrane multidrug resistance
pump, which is inhibited by CsA. Treatment with this drug
may therefore cause an increased mitochondrial ﬂuorescence
that can be erroneously interpreted as an increase of the
mitochondrial membrane potential. In order to prevent
this artifact and to normalize the loading conditions, in all
experiments with TMRM the medium was supplemented
with 1.6μM CsH, which inhibits the multidrug resistance
pump, but not the PTP [30]. At the end of each experiment,
mitochondria were fully depolarized by the addition of 4μM
of the protonophore carbonyl cyanide-p-triﬂuoromethoxy-
phenyl hydrazone. Clusters of several mitochondria were
identiﬁedasregionsofinterest,andﬁeldsnotcontainingcells
were taken as the background. Sequential digital images were
acquired every 2min.
2.6. Study Drug. CsA (sandimmun neoral) was given at
the dosage of 5mg/kg/die for one month [15] in the ﬁrst
4 patients and for 3 months in the last two patients.
After the initial period (1–3 months), a progressive taper-
ing was planned to perform long-term low-dose (1.25–
3mg/kg/die) maintenance therapy (targeting blood concen-
tration >200ng/mL 2h afterdosing). The daily dose was
taken in two divided doses (morning and evening), after
meals, dissolved in a drink. Serum concentration of CsA
was monitored to adapt the therapeutic dosage with a
target C2 levels in the range of 250–500ng/mL [31, 32].
CsA-induced nephrotoxicity rarely develops using doses
lower than 5mg/kg/day, and it is generally reversible upon
timely decrease of the dose of CsA or its discontinua-
tion if the serum creatinine levels increase >25% above
patients’ baseline values [31]. Blood CsA levels, predose and
two h afterdose, were determined with a no-pretreatment
monoclonal antibody-based immunoassay, aﬃnity-column-
mediated immunoassay (ACMIA) using Dimension Xpand-
HM for the measurement of CsA in whole blood.
2.7. Safety Evaluation. Side eﬀects were assessed using an
adverseeventschecklist,acompletebloodcount,andhepatic
and renal function tests, done at baseline and every 1–3
months.
2.8. Data Analysis. Data were analyzed with the unpaired
Students t-test, and values with P<0.05 were considered
as signiﬁcant. Descriptive analysis was computed for each
patient and for all patients. Continuous variables were
presented as mean.
3. Results
ThefeaturesofthepatientsaresummarizedinTable 1.ColVI
levels are based on immunoistochemistry as described in
original references [2, 14], which also contain further details
about the gene mutations and their mode of inheritance.
The three patients enrolled in the original pilot trial (P1,
P2, and P3) received CsA for 2 to 3.2 years and the three
new patients for 1 to 1.2 years (Table 2). The patients with
UCMD had a very low residual muscle strength at baseline,
11% of the predicted in age-/sex- matched population [33]
(Table 2). The megalimbs moved from 163.8N to 195.3N
in the six patients with a 19% mean increase (P value is
0.0597, considered not quite signiﬁcant; t = 2.425 with
5 degrees of freedom) (Table 2). Patient 5 had already an
evidentprogressionofthedisorderbeforestartingtreatment.
He was never able to run and lost the ability to rise from
the ﬂoor at the age of 6 and to climb stairs at 7. His total
body fat was 49% at age 6.5 (lean mass 12.7kg), 70% at4 Oxidative Medicine and Cellular Longevity
Table 1: Patient’s details. Phenotype, motor function, collagen VI type of expression in muscle or skin biopsies, and mutation in COL6A
genes are reported for each patient. All the patients had a UCMD clinical phenotype. At baseline, P5 and P6 were able to walk. ColVI levels
are based on immunoistochemistry as described in original references [2, 14]. Patients had mutations in each of the 3 COL6A genes both de
novo or compound heterozygous.
Patient Phenotype Collagen VI Mutation(s)
1 UCMD, NW M i l dr e d u c t i o ni nm u s c l eﬁ b e r s
and ﬁbroblasts COL6A1 de novo heterozygous Gly284Arg [14]
2 UCMD, NW Marked reduction in muscle
ﬁbers
COL6A2 compound heterozygous Gly487-Ala495delAspfsX48 and
Glu591-Cys605delThrfsX148 [2]
3 UCMD, NW Marked reduction in muscle
ﬁbers COL6A1 de novo heterozygous del275-280/insGlu275 [14]
4 UCMD, NW ND COL6A2 compound heterozygous Gly487-Ala495delAspfsX48 and
Glu591-Cys605delThrfsX148 [2]
5 UCMD, W Moderate reduction in muscle
ﬁbers
COL6A2 compound heterozygous intron 8c.927 + 5 G>Ah e t
p.Lys318fsX6
6 UCMD, W Moderate reduction in muscle
ﬁbers COL6A3 heterozygous G to Ant 6465 +1
UCMD: Ullrich congenital muscular dystrophy; W: walker; NW: nonwalker; ND: not done.
Table 2: Study results. The three patients enrolled in the original pilot trial (P1, P2, and P3) received CsA for 2 to 3.2 years and the three
new patients for 1 to 1.2 years. Megalimbs increased in all but P5. The distance walked in 6 minutes remained the same in the 2 patients able
to walk. Forced vital capacity declined in all from 57.1% predicted to 45.2% predicted.
Patient Age at treatment (Years) Age at Followup (Years) Megalimbs (Newton) 6MWD (meter) FVC %
Time 0 Followup Time 0 Followup Time 0 Followup
1 9.5 12.7 218 283 NA NA 47 24
2 9.8 11.6 106 142 NA NA 44 32
3 8.9 10.9 106 120 NA NA NA NA
4 9.0 10.2 140 169 NA NA 41.7 31
5 9.1 10.1 241 222 189 188 59 51
6 5.5 6.7 172 236 300 304 94 88
Mean 8.6 10.4 163.8 195.3 244.5 246 57.1 45.2
Megalimbs: sum of bilateral muscle strength of elbow ﬂexion, hand grip, knee ﬂexion, and knee extension; 6MWD: distance walked in 6 minutes; FVC %,
forced vital capacity % of predicted; NA: not able.
age 9.1 (lean mass 8.6kg) when he started the treatment, and
79% (lean mass 7.1kg) at the last followup one year later
(Table 3). If we consider P5 a nonresponder, in the other ﬁve
patients, the megalimbs increased from 148.4N to 190.0N
with a 28% mean increase (P value is 0.0142, considered
signiﬁcant; t = 4.159 with 4 degrees of freedom).
Motor function as assessed with the Muscular Dystrophy
Functional Grading Scale remained the same in all the
patients during the treatment period.
Respiratory function declined during the treatment
(Table 2). Apart from patient 3, who was not able to perform
spirometry because of limited bite opening, the other ﬁve
patients showed a steady decline (−7% per year) of the %
predicted forced vital capacity during the treatment period.
The two oldest patients (P1 and P2), who at the start of
treatmenthad already a FVC% of predicted below 50%, went
down to 24% and 32%, respectively and showed marked
oxygen desaturation at night. At this point (age 13 and 12),
CsA treatment was interrupted and they received noninva-
sive mechanical ventilation at night. Patient 3 experienced
with time symptoms of chronic hypoventilation like fatigue,
diurnal headache, and loss of weight and was scheduled
for evaluation of nocturnal oximetry and treatment. Patient
4 had an acute respiratory infection and died in few days
after exacerbating respiratory distress with the chest X-
ray showing bronchopneumonia, diaphragmatic paresis, and
a severely reduced chest volume. Autopsy showed severe
right ventricle hypertrophy consistent with a cor pulmonale,
generalized severe reduction of muscle ﬁbres that were
mostly replaced by ﬁbrotic tissue in the diaphragm and by
fat and ﬁbrosis in the other muscle groups [34]. These results
are within the frame of the course of respiratory function in
UCMD [7].
According to BMI (Table 3), 2 patients (3 and 6)
remained in the underweight category at baseline and
followup, one (patient 2) was in the healthy weight category
at baseline and moved to the obese category at followup, one
moved from the overweight to the obese (patient 5), and 2
patients (patient 1 and 4) remained in the obese category
at baseline and followup. However, DXA (Table 3) showed
that all the patients had already a high % of body fat at
baseline, including the 2 underweight. In addition, during
treatment, the lean mass decreased by 8.5%, while the fat
mass increased by 37.6% in 5 patients (Table 3). The patientsOxidative Medicine and Cellular Longevity 5
Table 3: Body composition evaluation: BMI and DXA. Body fat was estimated with the body mass index (BMI) and DXA. The BMI number
using the CDC BMI-for-age growth charts for girls and boys is translated into a percentile that categorizes the weight status. Two patients
(P3 and P6) remained in the underweight category during the study, one moved from the overweight to the obese (P 5), and 2 patients (P1
and P4) remained in the obese category at baseline and followup. However, all the patients had already a high % of body fat at baseline,
including the 2 underweight. In addition, the lean mass decreased by 8.5%, while the fat mass increased by 37.6% during the treatment in
5 patients. The patients had a marked reduction of total body BMD irrespective of the level of motor function: walkers and nonwalkers had
the same Z s c o r em e a nv a l u e( −3.8). The BMD was also not inﬂuenced by the treatment with CsA.
Patient
DXA
BMI (kg/m2) Lean Tissue Mass (kg) Fat Tissue Mass (kg) FAT% BMD Z score
Time 0 Followup Time 0 Followup Time 0 Followup Time 0 Followup Time 0 Followup
1 29.8 27.3 12.2 ND 40.7 ND 74 ND −4.3 ND
2 15.5 23.2 9.8 10.8 18.9 40.2 63 77 −3.1 −3.9
3 13.9 12.1 8.7 ND 10.1 ND 52 ND −4.1 ND
4 23.8 27.6 12.9 12.5 31.8 55.5 68 80 −3.6 −3.7
5 20.4 22.4 8.6 7.1 22.8 30.7 70 79 −4.6 −3.3
6 11.1 13.2 8.8 6.6 4.1 8.1 31 53 −3.1 −3.6
Mean 19.1 21.2 10.0∗ 9.2∗ 19.4∗ 33.6∗ 58∗ 72.2∗ −3.6∗ −3.6∗
BMI: body mass index; DXA: dual-energy X-ray absorptiometry; BMD: bone mineral density (g/cm2); ND: not done; ∗: mean of DXA data from patients 2,
4, 5, 6.
had a marked reduction of BMD irrespective of the level
of motor function: walkers and nonwalkers had the same Z
score mean value (−3.8). The BMD was not inﬂuenced by
the treatment with CsA.
Two patients experienced hyrsutism (1 and 3), which was
particularlyevidentinpatient1.Noneofthepatientsshowed
signs of renal dysfunction.
In keeping with the results obtained in cultures from the
ﬁrst 3 UCMD patients [15] after 1 month of CsA treatment,
the last 2 patients also showed that the mitochondrial
membrane potential response to oligomycin was largely
normalized in the muscle cells (Figure 1). If a threshold is
arbitrarily set at 90% ﬂuorescence, the number of cells with
depolarizing mitochondria shifted from 89%, 91%, 95%,
59%, and 69% to 45%, 38%, 41%, 13%, and 15% before
a n da f t e rt r e a t m e n tw i t hC s Af o rp a t i e n t s1 ,2 ,3 ,5 ,a n d6 ,
respectively (on average from 80.6% to 30.4%). These ﬁnd-
ings are in keeping with the results obtained in cultures from
UCMD patients [14] and in ﬁbers from Col6a1−/− mice [12],
and they indicate that, at the dose used in this study, CsA
reaches pharmacologically active concentrations in muscle.
The treatment with CsA in patients 5 and 6, like in
the ﬁrst 3 UCMD patients [15], also showed a signiﬁcant
decrease of the occurrence of apoptosis (Figure 2). The
incidenceofapoptosiswasassessedinthesamebiopticmate-
rials used for the measurements of mitochondrial function.
Unlike samples from healthy donors, where apoptosis was
almost undetectable (0.39 ± 0.3 per square millimeter) [15],
the samples from patients 5 and 6 had a number of apoptotic
nuclei(15.3 ±0.3persquaremillimeter),whichwereconsid-
erably decreased after CsA treatment (1.8 ± 0.9 per square
millimeter), indicating a cause-eﬀect relationship between
normalization of mitochondrial function and decreased cell
death.
After treatment with CsA, we found a statistically
signiﬁcant increased number of myoﬁbers positive for devel-
opmental myosin heavy chain also displaying diﬀusestaining
for desmin, which are characteristic signs of regeneration
[27, 35]. The eﬀect was particularly prominent in patients 1,
2, 3, and 6. Remarkably in patient 6, a marked regeneration
was still evident in the biopsy taken after 3 months (Figures
3 and 4). The search for necrotic ﬁbers with histochemical
analysis of acid phosphatase activity and anti-C5b9 antibody
was negative in all the biopsy taken before and after
treatmentwiththeexceptionofthebaselinebiopsyofpatient
5 where a unique necrotic ﬁber was detected.
4. Discussion
In ﬁve out of the six children with UCMD, the prolonged
CsA treatment resulted in an encouraging, statistically
signiﬁcant increase in the composite measure of muscle
strength. However, it should be noted that the muscle
strength improvement was not matched by a change in
motor function. In contrast with the positive impact on limb
muscle strength, CsA was not able to impede the progressive
deterioration of the respiratory function.
As we have already anticipated [15], the clinical eﬀect
of this treatment in attenuating progression of the disease
and/or in translating into a better muscle performance
depends on multiple factors, such as muscle loss and extent
of ﬁbrosis at the time of treatment, and potential for
muscle regeneration in individual patients. Therefore, the
discrepancy between the results of muscle function and
muscle strength may have diﬀerent explanations. Because in
the muscular dystrophy functional grading scales there are
only a few grades, improvement may not be noticed until
a consistent change occurs [36, 37]. A cardinal measure of
strength, like the isometric maximal voluntary contraction
estimated with a dynamometer, may show the trend much
sooner [36]. This is supported by the classic study of
Bohannon [38] who evaluated the eﬀect of resistant exercises
in patients with amyotrophic lateral sclerosis. There were
changes of 45 to 65 per cent in 14 of 18 muscles tested by6 Oxidative Medicine and Cellular Longevity
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Figure 1: Changes of mitochondrial TMRM ﬂuorescence induced by oligomycin in muscle cells isolated from patients before and after
treatment with CsA. Muscle cells obtained from biopsies of two patients (P5 in a and a ,P 6i nba n db  ) were seeded onto glass coverslips
precoated with laminin/poly-L-lysine, loaded with TMRM, and studied as described in Section 2. The procedure was repeated before
(a, b) and after (a ,b  ) 3 months of oral treatment with CsA. Where indicated, 6μM oligomycin (Oligo) and 4μM carbonylcyanide-p-
triﬂuoromethoxyphenyl hydrazone (FCCP) were added. Each line represents one individual cell. Depolarized cells were 59% before (a) and
13% after (a ) CsA treatment in Patient 5, and 69% before (b) and 15% after (b ) CsA treatment in Patient 6.
hand-held dynamometry measurements, but no change in
muscle graded strength. It should also be recognized that
the response of a treatment may vary in diﬀerent patients
with the same disorder [37]. Given the progressive nature
of UCMD, it was anticipated that the more eﬀective the
treatment is, the earlier it is started [37] when muscle
substitution/degenerationislesssevere.Theyoungesttreated
patient (patient 6) had in fact a good clinical result matched
by a more diﬀuse regeneration in the muscle biopsy taken
3 months after treatment. It has also been suggested that a
treatment would be more beneﬁcial in patients with Bethlem
myopathy, the milder form of the disease [34]. Another
possibility is that diﬀerent muscles may respond diﬀerently
to CsA. The selective involvement of diﬀerent muscles in
the muscular dystrophies is a consistent ﬁnding that has
repeatedly resisted explanation [39]. Gene expression studies
may help explain why generalized genetic insults lead to
consistent patterns of weakness that aﬀect some muscles
more than others [39] and why the same treatment has
diﬀerent impacts on diﬀerent muscles in the same patient
[40]. In particular, the diﬀerential eﬀect of CsA on limb
versus respiratory muscle strength could be related to
the grade of muscle involvement, with the more severely
aﬀected respiratory muscle being less prone to respond. The
diaphragm in fact is the most severely compromised muscle
in the otherwise mildly aﬀected Col6a1−/− mice [11]. The
diaphragm is also invariably aﬀected in UCMD patients,
causing early and severe respiratory insuﬃciency requiring
respiratory support in the ﬁrst or second decade of life [7,
10]. A generalized severe reduction of muscle ﬁbres that were
mostlyreplacedbyﬁbrotictissuewasfoundinthediaphragm
at autopsy of the patient who died after bronchopneumoniaOxidative Medicine and Cellular Longevity 7
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Figure 2:ApoptosisinmusclebiopsiesfromUCMDpatientsbefore
and after treatment with CsA. Biopsies from 5 patients with UCMD
(P1–P3, P5, and P6) were scored for the presence of apoptotic
nuclei with the TUNEL reaction as described in Section 2 before
(open bars) and after 1 month (P1–P3) or 3 months (P5, P6)
of oral treatment with 5mg 7kg CsA per day (ﬁlled bars). Data
are expressed as mean ± SEM of three independent experiments.
∗P<0.05. ∗∗P<0.01. The incidence of apoptotic nuclei in healthy
donor (control) biopsies was 0.39 ± 0.3 per square millimeter.
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Figure 3: Regeneration in muscle biopsies from UCMD patients
before and after treatment with CsA. Biopsies from 5 patients
with UCMD (P1–P3, P5, and P6) were scored for the presence of
regenerating ﬁbers (labeled with antibody against developmental
myosin heavy chain) as described in Methods before (open bars)
and after 1 month (P1–P3) or 3 months (P5, P6) of oral treatment
with 5mg 7kg CsA per day (ﬁlled bars). Data represent mean ± SD.
∗P<0.01.
[34]. A rapid progression of respiratory insuﬃciency has
beenconsistentlyrecognizedinUCMDpatients[6,10,37].A
reviewofthecourseofrespiratoryinsuﬃciencyin13patients
with UCMD showed that FVC has been found abnormal in
all patients from age 6 with a yearly decline (% predicted) of
6.6% from age 6 to 10 [7], 69.2% of patients were already
on noninvasive nocturnal ventilation, and 2 patients have
diedofrespiratoryinsuﬃciency[7].Apartfromthe6UCMD
patients in this study, 4 younger of 6 years and not able to
perform spirometry, we have followed other 4 patients, all of
them had a progressive decline of FVC, one died at 11 years
during an intercurrent respiratory illness, and the other 3
startedmechanicalventilationatameanageof11.1(SD2.8).
In our patients, the evaluation of body composition
gave some contrasting results between BMI and DXA. With
the DXA, all the patients had a marked excess of fat mass
in their body weight. The body fat was 58% of body
weight at baseline (range 31–74) and reached 72.2% at
followup (range 53%–80%). However, the weight status for
the calculated BMI-for-age percentile was for one of these
patients “healthy weight” and for 2 patients “underweight”.
It is clear that because BMI does not diﬀerentiate fat from
muscle mass, it is not the proper way to evaluate the body
composition of dystrophic patients. In addition, DXA clearly
documented the complete and progressive overturn of body
composition in UCMD patients with % body fat increasing
from 60.4 to 72.6 during the treatment period compared to
less than 30% of body fat in normal children [23]. BMD
was markedly decreased in UCMD patients compared with
healthy matched controls, and these diﬀerences in BMD
values were not correlated with the ambulatory status nor
with increasing age as it was found in Duchenne muscular
dystrophy patients [41].
The principal adverse reactions associated with the
use of CsA are renal dysfunction, hypertension, headache,
gastrointestinal disturbances, and hyrsutism/hypertrichosis.
Twoofourpatientshadhyrsutism/hypertrichosis,whichwas
more evident in patient 1, a female.
The biological results of this study conﬁrm the previous
ones [15] and prove that treatment with moderate doses of
CsAfavourablyaﬀectsmitochondrial functionincollagenVI
myopathies in vivo and dramatically decreases the frequency
of muscle cell death in the patients. Muscle ﬁber necrosis
was almost absent in the muscle biopsies of the UCMD
patients both before and after CsA treatment, conﬁrming
that in UCMD there are scarce necrotic ﬁbers [35, 42].
In the last two patients like in the ﬁrst 3 [15], we found
that regeneration was very limited at baseline, but signif-
icantly increased after CsA treatment for 3 and 1 month,
respectively. Interestingly, a peculiar pattern of regeneration
was found in 2 patients with advanced stage of UCMD
[35] and in patients with Bethlem myopathy [42]. The
Japanese authors [35], on the basis of the absent expression
of developmental myosin heavy chain in regenerating very
small calibered muscle ﬁbers, suggested that collagen VI
deﬁciency may disturb not only the mechanical integrity
of skeletal muscle ﬁbers but also ongoing regeneration
or complete maturation of muscle ﬁbers at least in the
advanced stage of UCMD. They also anticipated that it
would be important to determine if the lack of expression of
developmental myosin heavy chain is common to all patients
with UCMD, in particular in patients at early stages of the
disease [35]. Our ﬁndings show that younger patients with
UCMD express indeed developmental heavy chain in the
small regenerating ﬁbers and that the number of the very
small calibered regenerating ﬁbers expressing developmental8 Oxidative Medicine and Cellular Longevity
dMHC
(a)
Desmin
(b)
Merge
(c)
Figure 4: Regenerating muscle ﬁbers. Representative cross-section of the muscle biopsy of patient 6 after 3-month treatment with CsA. The
section was stained with DAPI to identify nuclei (blue) and with antibodies against developmental myosin heavy chain (dMHC, green),
as marker of regeneration, and desmin (red), as general marker of muscle cells. Several very small calibered muscle ﬁbers dMHC-positive,
which also display an intense and diﬀuse staining for desmin, are detected among myoﬁbers, pointing to an active regeneration process. Bar,
20μm.
heavy chain and desmin is signiﬁcantly increased compared
to baseline after CsA treatment. Our data suggest that in
younger patients with UCMD, the abnormal regeneration
or maturation processes are less aﬀected as compared to
the situation in older patients, and that CsA treatment is
eﬀective in correcting the abnormality. At ﬁrst sight, the
observation that treatment with CsA increased regeneration
may appear paradoxical because regeneration should match
the rate of muscle ﬁber death, which is lower when CsA is
present. An appealing explanation [15] is that in collagen
VI diseases, diﬀerentiating muscle cells are undergoing early
apoptosis together with mature ﬁbers, a situation that would
be similar to the ineﬀective erythropoiesis seen in many
hemoglobinopathies. By decreasing ineﬀective myogenesis,
CsA could increase the overall eﬃciency of muscle regenera-
tion, in keeping with the response of all patients.
The potential beneﬁt of CsA in UCMD patients must
be carefully weighed against the possible risks of immuno-
suppression. It should be mentioned, however, that other
cyclosporins, like MeAla3EtVal4-cyclosporin (Debio 025),
may represent an alternative to CsA [43]. We have shown
that Debio 025, a nonimmunosuppressive cyclosporin that
retainsthePTP-desensitizingpropertiesofCsA,isaseﬀective
as CsA at protecting mitochondrial function and preventing
apoptosis in muscle cultures from UCMD patients [14], a
ﬁndingthatholdsgreatpromiseforthetreatmentofcollagen
VI disorders.
After the completion of this trial, we have shown that
muscle pathology in Col6a1−/− mice lacking collagen VI
is ameliorated by a low-protein diet and by genetic and
pharmacologic approaches, including CsA, that activate
autophagy [44, 45]. The present as well as previous studies
[12, 14, 15, 44] are moving from the animal model of
collagen VI myopathy and its correction with drugs to
the conﬁrmation of the same pathogenesis and disease
correction in patients with Bethlem myopathy and UCMD.
5. Conclusions
Clariﬁcation of the pathogenic mechanisms of muscle ﬁber
damage in the animal model of collagen VI muscular dystro-
phies is allowing the rapid transfer to man of experimental
therapies based on inhibition of mitochondrial dysfunction
with CsA. The present demonstration that long-term treat-
ment with CsA ameliorates performance in speciﬁc muscles
of 5 out 6 UCMD patients and improves regeneration is
an encouraging result that raises some hope for the use of
cyclophilin inhibitors for the cure of this and possibly other
muscle diseases.
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